View Older Stories View More Recent Stories

Jun 3, 2021 10:00AM Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Cli
May 27, 2021 07:32AM Zynerba Pharma (ZYNE) Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 27, 2021 07:30AM Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 27, 2021 07:30AM Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 26, 2021 07:30AM Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:30AM Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 17, 2021 08:00AM Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
May 17, 2021 08:00AM Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
May 12, 2021 06:45AM Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
May 12, 2021 06:45AM Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
May 5, 2021 05:27PM Zynerba Pharma (ZYNE) Announces Phase 3 RECONNECT Trial Design for Zygel in Fragile X Syndrome
May 5, 2021 04:05PM Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
May 5, 2021 04:05PM Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
Apr 29, 2021 02:00PM Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Apr 29, 2021 02:00PM Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Apr 15, 2021 07:30AM Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Apr 6, 2021 07:30AM Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Mar 10, 2021 06:45AM Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 10, 2021 06:45AM Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 4, 2021 08:00AM Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
Jan 4, 2021 07:30AM Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
Jan 4, 2021 07:30AM Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
Dec 17, 2020 06:31AM Zynerba Pharma (ZYNE) Provides Regulatory Update on Zygel in Fragile X Syndrome
Dec 17, 2020 06:30AM Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
Dec 4, 2020 11:31AM Zynerba Pharmaceuticals (ZYNE) Presents New Data in Two Posters at AES
Dec 4, 2020 11:30AM Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
Nov 23, 2020 11:45AM Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
Nov 9, 2020 06:45AM Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Nov 9, 2020 06:45AM Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Oct 15, 2020 03:08PM Zynerba Pharma (ZYNE) New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder Presented at ICNC and CNS
Oct 15, 2020 03:07PM Zynerba Pharma (ZYNE) Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at ICNC and CNS
Oct 15, 2020 03:06PM Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th An
Oct 15, 2020 03:06PM Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49t
Oct 15, 2020 03:05PM New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Co
Oct 15, 2020 03:05PM New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Co
Oct 8, 2020 08:32AM Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
Oct 8, 2020 08:30AM Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting
Sep 17, 2020 01:59PM Zynerba Pharma (ZYNE) Confirms Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
Sep 17, 2020 01:55PM Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
Sep 14, 2020 06:55AM Zynerba Pharma (ZYNE) Provides Update on Recent Milestones
Sep 14, 2020 06:55AM Zynerba Pharmaceuticals Provides Update on Recent Milestones
Sep 10, 2020 07:30AM Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
Aug 10, 2020 06:45AM Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Aug 6, 2020 07:00AM Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
Jul 22, 2020 06:50AM Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup
Jul 22, 2020 06:50AM Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup
Jun 30, 2020 06:47AM Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical Significance
Jun 30, 2020 06:45AM Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome
Jun 30, 2020 06:45AM Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome
May 27, 2020 06:47AM Zynerba Pharma (ZYNE) Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in ASD
View More Recent Stories View Older Stories